The Next Wave of Immune Cell Therapy
From CAR T to eTCR: New immune cell therapies push beyond blood cancers
-
1
Kevin Tronkowski participated in a phase 1 clinical trial for engineered T-cell receptor (eTCR) T cells targeting colorectal cancer.
-
2
eTCR T cells are designed to target tumors with specific genetic mutations and require patients to meet certain eligibility criteria.
-
3
The development of eTCR T cells follows the success of CAR T cells, which are now standard treatments for certain blood cancers.
-
4
Both eTCR and CAR T cell therapies are engineered but differ in their mechanisms for targeting cancer cells.
-
5
Dana-Farber researchers are exploring eTCR T cells for solid tumors, expanding the potential of immune cell therapies beyond blood cancers.
